Marksans Pharma earnings calls.

Marksans Pharma delivered a strong Q2 FY26 with revenue of Rs 720.4 croreCurrent reported value: Rs 720.4 crore. No comparable prior figure is available in the source record. (up 12.2Current 12.2 crore vs previous available quarter 10.6 crore.% YoY), recovering from a softer Q1. US/North America drove growth at Rs 387 croreCurrent reported value: Rs 387 crore. No comparable prior figure is available in the source record. (27% YoY) on new launches in digestive health and pain management. EBITDA margin improved 391bps sequentially to 20.1Current 20.1 crore vs previous available quarter 21.3 crore.%, though down 108bps YoY due to UK pricing pressure and headcount addition at the Goa facility. PAT grew modest 1.4Current reported value: 1.4. No comparable prior figure is available in the source record.% to Rs 99.1Current reported value: 99.1. No comparable prior figure is available in the source record. crore. Management guided for sustained north of 20% EBITDA margins and targets Rs 3,000 crore revenue by FY28, scaling to Rs 5,000 crore in 5-7 years. Key growth vectors include German market entry in Q1 FY26, new UK product approvals (3 MHRA authorizations received), and capacity expansion at the old plant to 1.3 billion tablets. Working capital normalization to 120-130 days is expected from Q1 FY27 as inventory levels built during tariff uncertainty ease. Risk: UK pricing pressure remains intense and US tariff uncertainty, while partially resolved, still warrants monitoring.